Medically significant
A registered nurse spontaneously reported via a company employee that an approximately 52 year old female 
patient on TYSABRI (300 mg, IV, QM) for an unknown indication from unknown date to 01 Oct 2013 experienced 
suspected progressive multifocal leukoencephalopathy (onset 01 Oct 2013). According to the reporter, PML could 
not be confirmed because the patient did not want to have a MRI.  The patient died in (b) (6)  from suspected 
progressive multifocal leukoencephalopathy. It is unknown if autopsy was done. Treatment and lab testing for the 
event were not provided. The causality for the event of suspected progressive multifocal leukoencephalopathy is 
unknown.  TYSABRI therapy was discontinued.
Update 08 Sep 2015: Additional information was provided by the physician via the company representative that the 
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 383 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
patient's RRMS was diagnosed in 1993 (presumed indication for TYSABRI therapy). She had more or less 10 years
of Interferon (Betaferon (Interferon beta 1b) followed by Rebif (Interferon beta 1a)). After being on TYSABRI for 3 
years, a decision was made to stop TYSABRI in Oct 2013 due to positive anti JCV antibody (tested positive for the 
1st time) and cognitive symptoms (suspicion of PML). The patient did not want any treatment or investigation, so 
the PML couldn't be confirmed. Since Oct 2013 her neurologic status worsened slowly the first year, but the 
degradation was stronger this last 6 months with seizures and psychiatric symptoms (psychosis). She was in an 
institution specialized in palliative care and died in (b) (6)